
Balchem (BCPC) Stock Forecast & Price Target
Balchem (BCPC) Analyst Ratings
Bulls say
Balchem is poised for continued growth, as the company's reported financial results for the fourth quarter of 2025 showed record sales of $263.6 million, a 9.8% increase from the previous year. With a focus on human nutrition and health, the company's Strong HNH segment has been the driving force behind this growth, with projected revenue of $693 million in 2026 and $713 million in 2027. Additionally, Balchem's effective tax rate is expected to rise only modestly and the absence of tariffs on its nutraceutical products provides further competitive advantage in the market.
Bears say
Balchem is expected to continue facing challenges in its Animal Nutrition and Health segment, which has been negatively impacted by increased input costs. Despite a positive outlook for its Human Nutrition and Health segment, its overall valuation metrics have not improved, and the company is likely to be affected by continued market risks and uncertainties such as inflationary pressures and potential disruption to its European business. Our valuation approach yields a 12-month price objective of $190 per share, but significant risks remain, including slower growth in core businesses and potential hurdles in launching new products.
This aggregate rating is based on analysts' research of Balchem and is not a guaranteed prediction by Public.com or investment advice.
Balchem (BCPC) Analyst Forecast & Price Prediction
Start investing in Balchem (BCPC)
Order type
Buy in
Order amount
Est. shares
0 shares